Share This Article
Article Summary:
Chronic disease costs in the United States have become so normalized that we’ve stopped asking the obvious question: What if the system isn’t failing to prevent disease—what if it’s succeeding at profiting from it? Ninety percent of America’s $4.9 trillion annual healthcare bill flows to people already sick, and the financial incentives are perfectly aligned to keep it that way. The arrival of GLP-1 drugs like semaglutide and tirzepatide reveals this tension sharply: we finally have therapeutics that actually prevent chronic disease, yet the healthcare system’s core business model depends on chronic disease persisting. Cincinnati faces this reckoning acutely, with higher-than-average obesity and diabetes rates straining employers, schools, and nonprofit health systems caught between their mission to heal and their financial need for high patient volume.
The Numbers Are Obscene (And We’ve Stopped Noticing)
Ninety cents of every health care dollar in America flows to people already sick.
This isn’t a policy failure or a temporary market distortion. It’s the business model. Heart disease and stroke kill more than 843,000 Americans annually and will cost the system roughly $2 trillion by 2050. For the first time, global diabetes-related health expenditure surpassed $1 trillion USD in 2024. Alzheimer’s will balloon from $360 billion today to nearly $1 trillion by mid-century. The math is brutally simple: we spend vastly more on dialysis, amputations, and ICU stays than we ever spend preventing them. Chronic disease costs are staggering—a person with uncontrolled diabetes costs the system roughly 2.3 times what a person without it costs.
The scale is staggering and personal. Sixty-eight million Americans have arthritis. Thirty-five million have chronic kidney disease—90% don’t know it. Seven million have Alzheimer’s. Most people carry multiple conditions simultaneously. Add the hidden cost: $184.6 billion annually in lost productivity from cardiovascular disease alone. That’s wages not earned, businesses not started, caregivers not working. These aren’t abstract figures. They’re the economic architecture of a system that profits from chronic disease costs, not from preventing them.
The GLP-1 Moment: When Treatment Actually Works, the System Breaks
Semaglutide and tirzepatide do something the healthcare industry rarely sees: they actually work. These GLP-1 drugs don’t just manage obesity—they appear to prevent or reverse multiple chronic conditions simultaneously, from type 2 diabetes to cardiovascular disease. For the first time in decades, a pharmaceutical intervention reduces future disease burden rather than extending it.
But here’s the tension nobody wants to say aloud: if these drugs work as promised, they will eventually reduce the number of dialysis patients, cardiologists’ procedures, and endocrinologists’ office visits. The healthcare industry will shrink. So why are insurance companies already fighting coverage? Why does access depend on wealth? It raises an uncomfortable question: If a drug genuinely prevents disease, does the system want it to work?
What GLP-1 Drugs Revealed
Semaglutide and tirzepatide do something the healthcare system hasn’t seen in decades: they actually prevent disease instead of just managing it. These drugs don’t just suppress appetite—they appear to halt type 2 diabetes progression, reduce cardiovascular events, and lower cancer risk simultaneously. For patients, that’s extraordinary. For the system, it’s a problem.
Here’s the tension. A month of semaglutide or tirzepatide costs $1,000–$1,500. Insurance companies are already rationing access. Medicare limits coverage. The wealthy get the drug; the less fortunate get rationed. But the real issue is deeper: if GLP-1s work as promised, they’ll eventually eliminate thousands of dialysis patients, reduce cardiologists’ procedures, and shrink endocrinologists’ practices. The chronic disease costs that currently drive healthcare revenue will simply vanish. It raises an uncomfortable question: Does the system actually want this drug to work?
Prevention Doesn’t Scale (Because Nobody Profits From It)
A diabetes prevention program costs roughly $600 per person per year and reduces type 2 diabetes incidence by 58%. That’s one of the best returns on investment in medicine. Yet fewer than 5% of eligible Americans are enrolled. The reason isn’t medical—it’s financial. A prevention program generates no recurring revenue. A diabetes patient on metformin, insulin, and three other drugs, plus regular visits to ophthalmology, nephrology, and podiatry, generates $10,000–15,000 in annual healthcare revenue. A person who never gets diabetes generates zero.
The incentive structure is inverted. Hospitals and pharmaceutical companies profit from disease prevalence, not disease prevention. A cardiologist has no financial motivation to see you once a year for blood pressure checks; she has every motivation to see you five times a year after your heart attack. This isn’t cynicism. It’s accounting. The system isn’t broken—it’s optimized for the wrong outcome.
Cincinnati’s Specific Reckoning (Why This Matters Here)
Hamilton County’s chronic disease burden runs hotter than the national average: 42% obesity, 12% diabetes, cardiovascular disease rates that outpace most peer cities. That’s not abstract epidemiology—it’s money draining from employers, municipal budgets, and safety-net hospitals like UC Health and Mercy Health. Cincinnati Public Schools loses roughly 2.1 million instructional hours annually to dental emergencies alone, a preventable crisis that hits low-income neighborhoods hardest while kids from wealthy ZIP codes get braces. Meanwhile, the Tri-State’s aging manufacturing workforce is absorbing $15,000 to $18,000 per employee in annual healthcare costs plus lost productivity—a competitive disadvantage that compounds. Healthier regions attract healthier workers and healthier businesses.
Here’s the structural trap: UC Health and Mercy Health together employ over 30,000 people and control roughly 40% of regional healthcare spending. Both are mission-driven nonprofits, genuinely committed to the community. But their financial viability depends on high patient volume and high acuity. A genuinely healthy Cincinnati would shrink their revenue. This isn’t cynicism about individual administrators—it’s a system-level conflict of interest that no one person can resolve alone. The chronic disease burden that crushes Cincinnati’s budget constraints is also the revenue engine that sustains the institutions tasked with solving it.
What Happens When You Actually Try to Prevent Disease (The Uncomfortable Answer)
A handful of health systems have cracked the code. Kaiser Permanente operates on a capitated payment model: they receive a fixed fee per patient per year, regardless of how many times that patient needs care. The incentive flips instantly. Suddenly, prevention becomes profitable. Kaiser has lower obesity rates, better diabetes control, and lower overall costs than fee-for-service competitors. They profit by keeping people healthy—not by seeing sick people more often.
But Kaiser is an outlier. Most American healthcare operates on fee-for-service: you get paid for each visit, each test, each procedure. The more sick people you see, the more you earn. Shifting the entire U.S. healthcare system to capitation would require dismantling decades of financial incentives, renegotiating billions in contracts, and accepting that many healthcare jobs would disappear. Hospitals would need fewer emergency departments. Cardiologists would need fewer interventions. This is not a technical problem. It’s a political one. And it’s why chronic disease costs will keep rising.
The Therapeutics Trap (Why New Drugs Won’t Save Us)
GLP-1 drugs are remarkable. They work. But they also illustrate the system’s core dysfunction: we’re trying to solve a structural problem with a pharmaceutical solution. Obesity and type 2 diabetes aren’t primarily diseases of individual willpower or genetics. They’re diseases of environment, poverty, food deserts, work stress, and sleep deprivation. A drug that suppresses appetite doesn’t address any of that.
Moreover, semaglutide and tirzepatide will be expensive indefinitely. They’re patented. Patients need to stay on them forever. The pharmaceutical company profits perpetually. Compare this to a vaccine: one dose, immunity, revenue stops. Vaccines are cheaper to develop but less profitable than chronic therapies. New therapeutics are necessary. But if they’re the only lever we pull, we’re just making chronic disease costs more expensive and more medicalized. Cincinnati’s healthcare institutions will eventually have access to GLP-1s and whatever comes next. But access isn’t the same as equity. And equity isn’t the same as prevention.
What Cincinnati Could Actually Do (The Road Not Taken)
Cincinnati could start by inverting its incentives. Every dollar spent on a primary care doctor managing multiple chronic conditions saves five dollars in emergency visits and hospitalizations—yet the city faces a primary care shortage while specialists thrive. Paying primary care physicians competitively would require reversing decades of salary hierarchy, but it’s cheaper than dialysis.
More radically: fund prevention as public health infrastructure investments like schools or roads. Diabetes prevention programs, community health workers, and food access initiatives need public dollars, not market incentives. UC Health and Mercy Health could pilot a capitated model with Cincinnati Public Schools or P&G—a fixed fee per employee annually, regardless of visits. If it works over five years, the chronic disease burden Cincinnati carries becomes optional rather than inevitable.
The Question We’re Avoiding About Chronic Disease Costs
What’s less clear is whether Cincinnati’s nonprofit health systems actually want chronic disease costs to fall. UC Health and Mercy Health are mission-driven institutions genuinely committed to community health. But they’re also locked into a financial model where revenue scales with patient volume and disease severity. A healthier Cincinnati means fewer admissions, fewer procedures, fewer billable encounters. It means smaller budgets and smaller workforces.
This isn’t a moral failing—it’s structural. No CEO can simply decide to shrink their institution’s revenue in the name of prevention. The question isn’t whether they’re good people. It’s whether the system they operate within can ever incentivize them to make themselves obsolete. Until that changes, GLP-1 drugs and prevention programs will remain marginal interventions in a machine optimized to keep people sick enough to need managing.
Read More
Cincinnati Budget Deficit Could Shift Cuts Away From Police and Into City Services
FAQs
Why are GLP-1 drugs like Ozempic and Wegovy causing such a big deal if they actually work for weight loss and diabetes?
GLP-1 drugs work *too well* — and that’s exposing a fundamental problem with how we handle chronic disease. When these medications actually deliver results, they reveal that our healthcare system isn’t designed to handle effective prevention at scale. Suddenly insurers are scrambling to cover them, supply chains can’t keep up, and we’re spending billions on individual medications instead of addressing why 40% of Americans are pushing the scales in the first place. The real issue isn’t that GLP-1s are bad — it’s that we’ve built a system that profits more from managing disease than preventing it. When a drug works, it exposes how broken that system is.
If prevention is cheaper than treatment, why don't we just invest in prevention instead?
Great question, but here’s the catch: prevention doesn’t make money for anyone in particular. A drug company can’t patent ‘walk more and eat vegetables.’ There’s no recurring revenue from someone who never gets sick. Prevention requires sustained investment from government or employers with benefits that show up over *decades* — long after the politician or CEO who funded it is gone. Treatment, on the other hand, is billable, profitable, and shows immediate results. A hospital makes money every time someone gets dialysis for kidney disease, but nobody gets paid when that person never develops kidney disease in the first place. The system isn’t broken by accident — it’s structured this way.
What's the actual cost difference between preventing a chronic disease versus treating it?
The numbers are staggering. Preventing type 2 diabetes through lifestyle changes costs roughly $500-$1,000 per person over several years. Treating diabetes once someone has it? That’s $413 billion annually across the country — about $13,000 per person per year in medical costs and lost productivity. For heart disease, prevention through blood pressure management and exercise might cost a few hundred dollars. Treatment after a heart attack? Thousands for the acute care, then potentially tens of thousands annually for ongoing management. The CDC estimates that interventions to prevent and manage chronic diseases have ‘significant health and economic benefits,’ but we rarely see those benefits materialize because we don’t fund prevention at the scale we fund treatment. It’s not that prevention doesn’t work — it’s that we’ve chosen not to try it seriously.
Cincinnati specifically seems to have high rates of obesity and chronic disease — what makes this city's situation different?
Cincinnati isn’t unique — it’s just representative of what’s happening across the Midwest and in working-class communities nationwide. The city has higher obesity rates, higher rates of preventable disease, and lower income levels in many neighborhoods, which all correlate with chronic disease. What makes Cincinnati’s situation worth examining is that it’s a microcosm where you can actually *see* the choices being made. Are we investing in community health infrastructure, accessible gyms, food security, and preventive care? Or are we waiting until someone needs a GLP-1 prescription or dialysis? The uncomfortable answer for Cincinnati — and most American cities — is that we’ve built our systems around treatment after the fact. The road not taken would look like investing in the conditions that keep people healthy in the first place.
